Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2AMGN : Amgen's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
What is William Blair’s Forecast for Amgen Q4 Earnings?
Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...
pharmaphorum3d
Sanofi builds case for Sarclisa, challenging J&J’s Darzalex
IKEMA involved more than 300 relapsed myeloma patients and compared the drug to placebo when added to standard care with Amgen’s Kyprolis (carfilzomib) and dexamethasone in relapsed patients who ...
pharmaphorum3d
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
It has completed the IsKia study of Sarclisa added to the standard KRd regimen of Amgen's Kyprolis (carfilzomib), lenalidomide, and dexamethasone in previously untreated, transplant-eligible ...
Targeted Oncology2d
Orlowski Discusses Treatment Path Through Successive Relapses of Multiple Myeloma
During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...
DelveInsight Business Research, LLP: BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...